Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: Results of a target-driven active switch study

Current Medical Research and Opinion

Volumn 30, Issue 11, 2014, Pages 2139-2149

  Fleischmann, Roy ^a   Goldman, John A ^b   Leirisalo Repo, Marjatta ^c   Zanetakis, Ellen ^d   El Kadi, Hisham ^e   Kellner, Herbert ^f   Bolce, Rebecca ^g,h   Dehoratius, Raphael ^i,j   Wang, Jim ^k   Decktor, Dennis ^g,l  

^a METROPLEX CLINICAL RESEARCH CENTER   (United States)

^b Atlanta Research Center   (United States)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d Oklahoma Center for Arthritis Therapy and Research   (United States)

^e Rheumatology Arthritis and Osteoporosis Associates PA   (United States)

^f Division of Rheumatology   (Germany)

^g Janssen Biotech Inc   (United States)

^h Crescendo Bioscience   (United States)

ⁱ Janssen Pharmaceutical Companies of Johnson Johnson   (United States)

^j THOMAS JEFFERSON UNIVERSITY   (United States)

^k Janssen Research and Development   (United States)

^l REGENERON PHARMACEUTICALS INC   (United States)

more..

Author keywords

Anti infliximab antibodies; Anti TNF; Efficacy; Infliximab; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISONE; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; CARDIOGENIC SHOCK; CLINICAL DISEASE ACTIVITY INDEX; CONTINUOUS INFUSION; COUGHING; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART FAILURE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; OPEN STUDY; QUALITY OF LIFE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SHORT FORM 36; SIMPLIFIED DISEASE ACTIVITY INDEX; SINUSITIS; SUICIDE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; SINGLE BLIND PROCEDURE; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 84908610747     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.942416     Document Type: Review

References (40)

1. Hochberg MC, Tracy JK, Hawkins-Holt M, et al. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl 2):13-16
2. Wiens A, Venson R, Correr CJ, et al. Meta-Analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010;30:339-53
3. Alivernini S, Laria A, Gremese E, et al. ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. Arthritis Res Ther 2009;11:R163
4. Erickson AR, Mikuls TR. Switching anti-TNF-Alpha agents: what is the evidencė. Curr Rheumatol Rep 2007;9:416-20
5. Hyrich KL, Lunt M, Watson KD, et al; for the British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-Tumor necrosis factor alpha agent to a second anti-Tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20
6. Scrivo R, Conti F, Spinelli FR, et al. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature. Reumatismo 2009;61:107-17
7. Chatzidionysiou K, Askling J, Eriksson J, et al.; for the ARTIS group. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis 2014: published online 15 January 2014, doi: 10.1136/annrheumdis-2013-204714
8. Conti F, Scrivo R, Spinelli FR, et al. Outcome in patients with rheumatoid arthritis switching TNF-Alpha antagonists: a single center, observational study over an 8-year period. Clin Exp Rheumatol 2009;27:540-1
9. Bingham III CO, Ince A, Haraoui B, et al. Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study. Curr Med Res Opin 2009;25:1131-42
10. Cohen G, Courvoisier N, Cohen JD, et al. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005;23:795-800
11. Furst D, Gaylis N, Bray V, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the OPPOSITE study. Ann Rheum Dis 2007;66:893-9, comment in: Ann Rheum Dis 2007;66:849-51
12. Hansen KE, Hildebrand JP, Genovese MC, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004;31:1098-102
13. Laas K, Peltomaa R, Kautiainen H, et al. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis. Clin Rheumatol 2008;27:927-32
14. van Vollenhoven R, Harju A, Brannemark S, et al. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor a blockers can make sense. Ann Rheum Dis 2003;62:1195-8
15. Van Gestel AM, Prevoo ML, vant Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40, comment in: Arthritis Rheum 1998;41:942-5
16. Prevoo ML, vant Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8
17. van Gestel A, Stucki G. Evaluation of established rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 1999;13:629-44
18. van Riel PL, van Gestel AM, Scott DL. EULAR Handbook of Clinical Assessments in Rheumatoid Arthritis. Alphen Aan Den Rijn, The Netherlands: Van Zuiden Communications BV, 2000
19. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40
20. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35
21. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42: 244-57
22. Aletaha D, Smolen JS. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 2007;21:662-75
23. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806
24. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45
25. Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patients perspective. J Rheumatol 1993;20:557-60
26. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form healthy survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
27. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohns Disease. Clin Gastroenterol Hepatol 2004;2:542-53
28. Westhovens R, Yocum D, Han J, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006;54:1075-86, erratum in Arthritis Rheum 2007;56:1675
29. van Vollenhoven RF, Klareskog L. Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE. Scand J Rheumatol 2007;36:418-23
30. Bombardieri S, Ruiz AA, Fardellone P, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-Antagonist therapy in clinical practice. Rheumatology (Oxford) 2007;46:1191-9
31. Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-Tumour necrosis factor therapy. Ann Rheum Dis 2008;67:547-54
32. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-Tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23
33. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-Tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806
34. Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 2004;31:1538-45
35. Gilbert Jr TD, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskel Dis 2004;5:36
36. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:638-43
37. Hyrich KL, Lunt M, Dixon WG, et al; on behalf of the BSR Biologics Register. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology 2008;47: 1000-5
38. Smolen JS, van Der Heijde DM, St Clair EW, et al. Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset (ASPIRE) study group. Arthritis Rheum 2006;54:702-10
39. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-Tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63
40. van Der Laken CJ, Voskuyl AE, Roos JC, et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007;66:253-6